Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia

被引：5
|
作者：
Kurata, Yu [1 ]
Tanaka, Tetsuhiro [1 ]
Nangaku, Masaomi [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Div Nephrol & Endocrinol, Tokyo, Japan
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
基金：
日本学术振兴会;
关键词：
HYPOXIA-INDUCIBLE FACTOR; KIDNEY; DISEASE; ANGIOGENESIS; ACTIVATION; EXPRESSION; INJURY; ALPHA;
D O I：
10.21037/atm.2019.09.118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia
    Tanaka, Mototsugu
    Ikuma, Mutsuhiro
    Asakura, Wataru
    Fujiwara, Yasuhiro
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (02) : 358 - 361
  • [2] HIF prolyl hydroxylase inhibitors for anemia
    Muchnik, Eugene
    Kaplan, Joshua
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (05) : 645 - 656
  • [3] Giving Anemia a Boost with Inhibitors of Prolyl Hydroxylase
    Denny, William A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (07) : 2943 - 2944
  • [4] Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
    Kambara, Takahiro
    Shibata, Rei
    Sakamoto, Yuusuke
    Sakaguchi, Teruhiro
    Osanai, Hiroyuki
    Nakashima, Yoshihito
    Asano, Hiroshi
    Murohara, Toyoaki
    Ajioka, Masayoshi
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [5] Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
    Takahiro Kambara
    Rei Shibata
    Yuusuke Sakamoto
    Teruhiro Sakaguchi
    Hiroyuki Osanai
    Yoshihito Nakashima
    Hiroshi Asano
    Toyoaki Murohara
    Masayoshi Ajioka
    BMC Research Notes, 17
  • [6] Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection
    Juan Antonio Requena-Ibáñez
    Carlos G. Santos-Gallego
    Anderly Rodriguez-Cordero
    M. Urooj Zafar
    Juan José Badimon
    Cardiovascular Drugs and Therapy, 2022, 36 : 1187 - 1196
  • [7] Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection
    Requena-Ibanez, Juan Antonio
    Santos-Gallego, Carlos G.
    Rodriguez-Cordero, Anderly
    Zafar, M. Urooj
    Badimon, Juan Jose
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) : 1187 - 1196
  • [8] Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
    Sugahara, Mai
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    KIDNEY INTERNATIONAL, 2017, 92 (02)
  • [9] Updates on hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of renal anemia
    Li, Jing
    Haase, Volker H. H.
    Hao, Chuan-Ming
    KIDNEY DISEASES, 2023, 9 (01) : 1 - 11
  • [10] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Cases, A.
    Vera, M.
    Ojeda, R.
    Gorriz, J. L.
    DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
12345